Your browser doesn't support javascript.
loading
COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality -cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM).
Garnica, Marcia; Crusoe, Edvan De Queiroz; Ribeiro, Glaciano; Bittencourt, Rosane; Magalhães, Roberto José Pessoa; Zanella, Karla Richter; Hallack Neto, Abrahão Elias; Lima, Juliana Souza; Solo, Caroline Bonamin; Souza, Emmanuella Graciott; Fernandes, Andre Magalhaes; Maiolino, Angelo; Hungria, Vania.
Afiliação
  • Garnica M; Universidade Federal do Rio de Janeiro (UFRJ), Brazil; Tranplant Unit, Complexo Hospitalar de Niterói (DASA - CHN), Brazil. Electronic address: marciagarnica@hucff.ufrj.br.
  • Crusoe EQ; Hospital Universitário Professor Edgar Santos (HUPES), Universidade Federal da Bahia, Brazil.
  • Ribeiro G; Universidade Federal de Minas Gerais, Brazil.
  • Bittencourt R; Universidade federal do Rio Grande do Sul, Brazil.
  • Magalhães RJP; Universidade Federal do Rio de Janeiro (UFRJ), Brazil.
  • Zanella KR; Clinica Viver- CEPHON, Florianópolis, Brazil.
  • Hallack Neto AE; Universidade Federal de Juiz de Fora, Brazil.
  • Lima JS; IHOC/Curitiba, Curitiba, Brazil.
  • Solo CB; HC - UFPR, Curitiba, Brazil.
  • Souza EG; Universidade Federal de Minas Gerais, Brazil.
  • Fernandes AM; Clinica CEHON- Juazeiro, Brazil.
  • Maiolino A; Universidade Federal do Rio de Janeiro (UFRJ), Brazil; Américas Centro de Oncologia Integrado, Brazil.
  • Hungria V; Hematology, Santa Casa Medical School, Brazil; São Germano Clinic, Brazil.
Hematol Transfus Cell Ther ; 2023 Sep 13.
Article em En | MEDLINE | ID: mdl-37718131
INTRODUCTION: This study evaluated outcomes and risk factors for COVID-19 in 91 Brazilian multiple myeloma (MM) patients between April 2020 and January 2022. RESULTS: Of the 91 MM patients diagnosed with COVID-19, 64% had comorbidities and 66% required hospitalization due to COVID-19, with 44% needing ventilatory support and 37% intensive care. Age (OR 2.02; 95%CI 1.02 - 7.7) and hypertension OR 4.5; 95%CI 1.3 - 15.5) were independently associated with hospitalization and certain MM therapies (corticosteroids and monoclonal drugs) were associated with ventilatory support (OR 4.3; 95%CI 1.3 - 14 and OR 5.7; 95%CI 1.8 - 18, respectively), while corticosteroids and immunomodulatory drugs were linked to ICU admission (OR 5.1; 95% CI 1.4 - 18 and OR 3.4; 95%CI 1.1 - 10, respectively). The overall mortality rate was 30%, with the highest rate observed in the ICU (73%). Additionally, the ECOG performance status was linked to increased mortality (OR 11.5; 95%CI 1.9 - 69). The MM treatment was delayed in 63% of patients who recovered from COVID-19. CONCLUSIONS: The findings highlight the need for preventing COVID-19 and prioritizing vaccination among MM patients, as they have high rates of severe outcomes in the event of COVID-19. It is also essential to monitor the potential clinical impacts of COVID-19 on MM patients in the long-term. Given the limited resources available in treating MM patients in Brazil during the COVID-19 pandemic, outcomes might be worse in this population.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies País/Região como assunto: America do sul / Brasil Idioma: En Revista: Hematol Transfus Cell Ther Ano de publicação: 2023 Tipo de documento: Article País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies País/Região como assunto: America do sul / Brasil Idioma: En Revista: Hematol Transfus Cell Ther Ano de publicação: 2023 Tipo de documento: Article País de publicação: Brasil